Sponsors (112)
The bill standardizes federal scheduling and enforcement for xylazine to improve detection, prosecution, and oversight of illicit use, but does so at the cost of higher compliance burdens, potential access limits for legitimate users, greater criminalization risk, and added strains on public‑health and social‑service responses.
Law enforcement, prosecutors, and federal agencies get a clear statutory definition, federal scheduling authority, and enforcement tools for xylazine, reducing legal ambiguity for investigations and prosecutions.
Tighter federal controls and the ability to seize/regulate xylazine-containing products could help limit illicit supply and reduce xylazine-adulterated opioid harms and related overdoses.
Establishing a single federal schedule (Schedule III) and related clarifications reduces ambiguity for manufacturers and distributors about legal status and recordkeeping expectations.
Patients and legitimate users may face reduced access to xylazine-containing products and higher costs as manufacturers and providers confront new DEA registration, recordkeeping, and security requirements.
Broader statutory definitions (including salts/isomers) and prohibitions on any quantity increase the risk that people with trace contamination or incidental possession will be criminally charged.
Stricter or clarified federal penalties could raise incarceration rates and costs, and may disproportionately harm communities already targeted by drug enforcement.
Based on analysis of 7 sections of legislative text.
Designates xylazine and any product containing it as a Schedule III controlled substance, adds transition rules, directs sentencing review, and requires two reports to Congress.
Official title: To prohibit certain uses of xylazine, and for other purposes.
Introduced February 12, 2025 by James Varni Panetta · Last progress February 12, 2025
Designates xylazine and any material, compound, mixture, or preparation containing any quantity of xylazine as a Schedule III controlled substance under the Controlled Substances Act, establishes a statutory definition of xylazine, and creates a special "ultimate user" definition and transition rules to delay some Schedule III operational requirements for affected parties. The bill also directs the U.S. Sentencing Commission to review federal drug sentencing policy for offenses involving xylazine and requires two reports to Congress on illicit xylazine sources, diversion, and trends.